Hydrogen sulfide prevents arterial medial calcification in rats with diabetic nephropathy.

Hydrogen sulfide prevents arterial medial calcification in rats with diabetic nephropathy.
复制标题

DOI:
10.1186/s12872-021-02307-9
复制
发表时间:
2021-10-13
影响因子:
2.1
通讯作者:
Zhou YB
Zhou YB
中科院分区:
医学4区
文献类型:
--
作者:
Wang FZ;Zhou H;Wang HY;Dai HB;Gao Q;Qian P;Zhou YB

文献摘要

参考文献

相似文献

Arterial medial calcification (AMC) is associated with a high incidence of cardiovascular risk in patients with type 2 diabetes and chronic kidney disease. Here, we tested whether hydrogen sulfide (H2S) can prevent AMC in rats with diabetic nephropathy (DN). DN was induced by a single injection of streptozotocin and high-fat diet (45% kcal as fat) containing 0.75% adenine in Sprague–Dawley rats for 8 weeks. Rats with DN displayed obvious calcification in aorta, and this was significantly alleviated by Sodium Hydrosulfide (NaHS, a H2S donor, 50 μmol/kg/day for 8 weeks) treatment through decreasing calcium and phosphorus content, ALP activity and calcium deposition in aorta. Interestingly, the main endogenous H2S generating enzyme activity and protein expression of cystathionine-γ-lyase (CSE) were largely reduced in the arterial wall of DN rats. Exogenous NaHS treatment restored CSE activity and its expression, inhibited aortic osteogenic transformation by upregulating phenotypic markers of smooth muscle cells SMα-actin and SM22α, and downregulating core binding factor α-1 (Cbfα-1, a key factor for bone formation), protein expressions in rats with DN when compared to the control group. NaHS administration also significantly reduced Stat3 activation, cathepsin S (CAS) activity and TGF-β1 protein level, and improved aortic elastin expression. H2S may have a clinical significance for treating AMC in people with DN by reducing Stat3 activation, CAS activity, TGF-β1 level and increasing local elastin level. The online version contains supplementary material available at 10.1186/s12872-021-02307-9.
DOI: 10.1016/j.carpath.2006.07.001
发表时间: 2007-01-01
影响因子: 3.7
作者:
LaShan Simpson, Chartrisa;Lindley, Suzanne;Vyavahare, Narendra R.
通讯作者: Vyavahare, Narendra R.
DOI: 10.1093/cvr/cvy010
发表时间: 2018-03-15
影响因子: 10.8
作者:
Durham AL;Speer MY;Scatena M;Giachelli CM;Shanahan CM
通讯作者: Shanahan CM
DOI: 10.1161/hypertensionaha.111.00299
发表时间: 2013-02
期刊: Hypertension (Dallas, Tex. : 1979)
影响因子: --
作者:
Johnson AW;Kinzenbaw DA;Modrick ML;Faraci FM
通讯作者: Faraci FM
DOI: 10.1016/j.jvs.2015.01.026
发表时间: 2015-06-01
影响因子: 4.3
作者:
Georgiadis, George S.;Argyriou, Christos;Lazarides, Miltos K.
通讯作者: Lazarides, Miltos K.
DOI: 10.1093/ndt/gfl429
发表时间: 2006-12-01
影响因子: 6.1
作者:
Chen, Neal X.;Duan, Danxia;Moe, Sharon M.
通讯作者: Moe, Sharon M.